Bank of New York Mellon Increases Substantial Holding Post-Reverse Split
ATHE sits 85% above its 52-week low of $2.66.
Summary
The Bank of New York Mellon, as ADR depositary, increased its reported substantial holding in Alterity Therapeutics to 27.23% post-reverse split, reflecting a higher aggregate proportion of shares held as ADRs.
Key Events · Ownership and Investor Activity · ATHE
-
Substantial Holding Increased
The Bank of New York Mellon Corporation, as ADR depositary, increased its reported substantial holding from an adjusted 26.22% to 27.23% of ordinary shares.
-
Post-Split Adjustment
The reported change accounts for the company's recent 1-for-50 reverse stock split, showing a net increase in the depositary's equivalent share count.
-
Reversal of Trend
This increase reverses a previously reported decline in the ADR depositary's percentage ownership.
Analysis · ATHE · Life Sciences
This filing indicates that The Bank of New York Mellon Corporation, in its capacity as the ADR depositary, has increased its reported substantial holding in Alterity Therapeutics. After adjusting for the recent 1-for-50 reverse stock split, their relevant interest rose from an equivalent of 26.22% to 27.23% of the company's ordinary shares. This net increase in percentage ownership suggests a growing proportion of the company's shares are held through the ADR program, reversing a previously reported decline in ADR depositary ownership.
At the time of this filing, ATHE was trading at $4.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.4M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.